| Line Item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Insurance revenue | ||||
| Healthcare services revenue | ||||
| Sales of medicines | ||||
| Total revenue from contracts with customers | ||||
| Cost of sales and services | ||||
| Gross profit | ||||
| Selling expenses | ||||
| Administrative expenses | ||||
| Loss for impairment of trade receivables | ||||
| Other expenses | ||||
| Other income | ||||
| Operating profit | ||||
| Finance income | ||||
| Finance income from exchange difference | ||||
| Finance costs | ||||
| Finance costs from exchange difference | ||||
| Net finance cost | ||||
| Share of profit of equity-accounted investees | ||||
| Income (loss) before tax | ||||
| Income tax expense | ||||
| Profit (loss) for the year | ||||
| Other comprehensive income | ||||
| Cash flow hedges | ||||
| Foreign operations – Foreign currency translation differences | ||||
| Remeasurements of defined benefit liability | ||||
| Change in fair value of put liability | ||||
| Other investments at FVOCI – net change in fair value | ||||
| Equity-accounted investees – share of OCI | ||||
| Income tax | ||||
| Other comprehensive income (loss) for the year, net of tax | ||||
| Total comprehensive income (loss) for the year | ||||
| Owner of the Company | ||||
| Non-controlling interest | ||||
| Profit (loss) for the year | ||||
| Earnings per share | ||||
| Basic earnings per share | ||||
| Diluted earnings per share |